Louis G. Lange
CIK: 0001238401
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
NewAmsterdam Pharma Co N.V.
Discretionary Trading P&L
Holdings
Transaction History (12 total)
- Mar 11, 2026NAMS
NewAmsterdam Pharma Co N.V.
Sale(S)Direct44.2K shares at avg. $30.41$1.3M - Mar 11, 2026NAMS
NewAmsterdam Pharma Co N.V.
Sale(S)Direct446 shares at avg. $31.23$14K - Mar 9, 2026NAMS
NewAmsterdam Pharma Co N.V.
In-the-Money(X)Direct44.6K shares at avg. $11.50$513K - Mar 6, 2026NAMS
NewAmsterdam Pharma Co N.V.
Sale(S)Indirect28.2K shares at avg. $29.41$829K - Jan 7, 2026NAMS
NewAmsterdam Pharma Co N.V.
Award(A)Direct3.4K shares- - Jun 1, 2025NAMS
NewAmsterdam Pharma Co N.V.
Exercise(M)Indirect68 shares- - May 1, 2025NAMS
NewAmsterdam Pharma Co N.V.
Exercise(M)Indirect69 shares- - Apr 14, 2025NAMS
NewAmsterdam Pharma Co N.V.
Exercise(M)Indirect69 shares- - Mar 26, 2025NAMS
NewAmsterdam Pharma Co N.V.
Exercise(M)Direct3.1K shares- - Mar 26, 2025NAMS
NewAmsterdam Pharma Co N.V.
Award(A)DirectRestricted Stock Unit
3.3K shares- - Jan 7, 2025NAMS
NewAmsterdam Pharma Co N.V.
Award(A)Direct7K shares- - Jan 6, 2025NAMS
NewAmsterdam Pharma Co N.V.
Award(A)DirectOption (right to buy)
32.5K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Mar 11, 2026 | NAMS NewAmsterdam Pharma Co N.V. | Sale(S) | 44,173 | $30.41 | $1,343,301 | Direct |
| Mar 11, 2026 | NAMS NewAmsterdam Pharma Co N.V. | Sale(S) | 446 | $31.23 | $13,929 | Direct |
| Mar 9, 2026 | NAMS NewAmsterdam Pharma Co N.V. | In-the-Money(X) | 44,619 | $11.50 | $513,119 | Direct |
| Mar 6, 2026 | NAMS NewAmsterdam Pharma Co N.V. | Sale(S) | 28,186 | $29.41 | $828,950 | Indirect |
| Jan 7, 2026 | NAMS NewAmsterdam Pharma Co N.V. | Award(A) | 3,400 | - | $0 | Direct |
| Jun 1, 2025 | NAMS NewAmsterdam Pharma Co N.V. | Exercise(M) | 68 | - | - | Indirect |
| May 1, 2025 | NAMS NewAmsterdam Pharma Co N.V. | Exercise(M) | 69 | - | - | Indirect |
| Apr 14, 2025 | NAMS NewAmsterdam Pharma Co N.V. | Exercise(M) | 69 | - | - | Indirect |
| Mar 26, 2025 | NAMS NewAmsterdam Pharma Co N.V. | Exercise(M) | 3,102 | - | - | Direct |
| Mar 26, 2025 | NAMS NewAmsterdam Pharma Co N.V. | Award(A) Restricted Stock Unit | 3,308 | - | - | Direct |
| Jan 7, 2025 | NAMS NewAmsterdam Pharma Co N.V. | Award(A) | 6,960 | - | $0 | Direct |
| Jan 6, 2025 | NAMS NewAmsterdam Pharma Co N.V. | Award(A) Option (right to buy) | 32,500 | - | - | Direct |
1-12 of 12 transactions
About LANGE LOUIS G
LANGE LOUIS G (SEC CIK 0001238401) files insider reports with the SEC as Director of NewAmsterdam Pharma Co N.V. (NAMS).
Signal8 holds 8 ownership filings by LANGE LOUIS G, all Form 4s, filed between Jan 8, 2025 and Mar 12, 2026. Those filings report 12 transactions, from Jan 6, 2025 to Mar 11, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on LANGE LOUIS G's filings is in NAARDEN, P7.
Recent filings by LANGE LOUIS G
- Mar 11, 2026: Open-market sales of NAMS shares (2 lines, Form 4, code S).
- Mar 9, 2026: Option exercise of NAMS shares (Form 4, code X).
- Mar 6, 2026: Open-market sale of NAMS shares (Form 4, code S).
- Jan 7, 2026: Grant or award of NAMS shares (Form 4, code A).
- Jun 1, 2025: Option exercise of NAMS shares (Form 4, code M).
Other insiders filing for NewAmsterdam Pharma Co N.V. (NAMS)
- Kastelein Johannes Jacob Pieter, Chief Scientific Officer
- Davidson Michael H., Chief Executive Officer
- Smither John W, Director
- Gunning Robert William, Vice President, Controller
- Kooij Louise Frederika, Chief Accounting Officer
- Somaiya Mayur Ian, Chief Financial Officer